Personalised medicine to relieve the health service
Smaller patient groups and targeted treatments are the future of cancer care in Norway.
Nine countries met in Oslo last week to discuss how to establish National Cancer Mission Hubs in their respective EU member states or associated countries.
For more information about Cancer Mission Hub Norway, please visit: https://www.cancermission.no
Dec 10, 2024
Sofia Linden
The European Union has set the ambitious goal to improve the lives of three million people living with cancer by 2030. To reach this target, the EU project ECHoS was launched with the aim of supporting the creation of National Cancer Mission Hubs.
Last week, representatives of the ECHoS project from Norway, Ireland, Belgium, France, Netherlands, Italy, Portugal, Greece and Romania met in Oslo for a two-day knowledge exchange programme.
No one-size-fits-all model
The delegates kicked off the first day at Oslo Cancer Cluster with a tour de table, where they shared insights on setting up national mission hub-like structures in their respective countries.
“From the early stage of the project, it was clear that there is no one-size-fits-all model for National Cancer Mission Hubs. Yet, we all share the same overarching goal and it’s inspiring to see how each partner is designing solutions that are tailored to the unique needs of their oncology ecosystem”, said Marine Jeanmougin, Lead EU affairs and digital innovation at Oslo Cancer Cluster.
How to engage stakeholders
The second part of the day was spent on a stakeholder engagement workshop. One important aspect of the Mission on Cancer is to involve all sectors across the Penta Helix model, which includes the commercial sector, health and care services, public administration, citizens and civil society, and academic institutions, on a national, regional and local level.
The workshop gave the participants the opportunity to share best practices and challenges when it comes to understanding their ecosystem, developing engagement strategies, building partnerships, and fostering sustainable engagement.
“Inputs from participating countries will contribute to the development of a playbook that offers frameworks, resources, practical tips, and real-world insights on stakeholder engagement for National Cancer Mission Hubs. Examples from the collaborative efforts of the virtual All-Island Cancer Research Institute (AICRI) or the stakeholder engagement initiatives led by InoMed in the GUIDE.MRD project were particularly inspiring. The Norwegian partners also shared key learnings from their public-private partnership initiative, CONNECT, demonstrating how collaboration across the Penta Helix can effectively support the implementation of precision cancer medicine,” said Jeanmougin.
A focus on patients
Day two was held at the Norwegian Cancer Society’s Science Centre in Oslo. Two central themes of the day were citizen engagement and patient participation.
Astrid Bjerke, strategic adviser at the Norwegian Cancer Society, gave an overview of the many ways the Cancer Society has worked with citizen engagement. This includes funding research, supporting user participation, influencing policy, doing advocacy work, setting up patient user panels, running awareness campaigns and more. They have experimented with town hall meetings across Norway to put a focus on the patient journey from hospital to municipality.
“Grand challenges require big enthusiastic engagement from citizens and patients to create change. Patients and citizens should be at the core of any activity. WHO defines citizen engagement as a deliberate form of public participation to inform effective policy making. At the Norwegian Cancer Society, this is really important to us, as we say ‘No decision about me, without me’,” commented Bjerke.
This was followed by a lively discussion among the participants on what is meant by patient and citizen engagement, where to draw on expertise, and how to take it to the next level.
Stine Bergliot Høibakk Nilsen, Public Affairs Manager at the Norwegian Cancer Society, presented more about the organisation’s work on patient participation. Finally, Ole Alexander Opdalshei introduced how the Cancer Society involves patients in research projects.
Funded by the European Union under the Horizon Europe Framework Programme. Grant Agreement Nº: 101104587.
Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them.
Smaller patient groups and targeted treatments are the future of cancer care in Norway.
Geir Hetland, Chief Financial Officer of Thermo Fisher Scientific, is the latest addition to the board of Oslo Cancer Cluster.